Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

27.22 +0.72 (+2.72%)
Streaming Delayed Price Updated: 3:53 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 531,568
Open 26.66
Bid (Size) 27.22 (5)
Ask (Size) 27.28 (1)
Prev. Close 26.50
Today's Range 26.66 - 27.43
52wk Range 19.73 - 47.32
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
From Veracyte, Inc.
Via Business Wire
VERACYTE INC (NASDAQ:VCYT) – A Promising Affordable Growth Stock in Biotechnology
VERACYTE INC (NASDAQ:VCYT) is a biotechnology stock with strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth... 
Via Chartmill

Performance

YTD
-32.7%
-32.7%
1 Month
-14.1%
-14.1%
3 Month
-30.8%
-30.8%
6 Month
-33.8%
-33.8%
1 Year
+26.9%
+26.9%

More News

Read More
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For May 7, 2025
Via Benzinga
A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts
Via Benzinga
Breaking Down Veracyte: 7 Analysts Share Their Views
Via Benzinga
Veracyte Announces First Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch
Via Chartmill
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms
Via Benzinga
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
From Veracyte, Inc.
Via Business Wire
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
Via Investor's Business Daily
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
From Veracyte, Inc.
Via Business Wire
Despite its growth, VERACYTE INC (NASDAQ:VCYT) remains within the realm of affordability.
Via Chartmill
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
From Veracyte, Inc.
Via Business Wire
While growth is established for VERACYTE INC (NASDAQ:VCYT), the stock's valuation remains reasonable.
Via Chartmill
5 Analysts Assess Veracyte: What You Need To Know
Via Benzinga
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
From Veracyte, Inc.
Via Business Wire
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Via Benzinga
VERACYTE INC (NASDAQ:VCYT) stands out as a growth opportunity that won't break the bank.
Via Chartmill
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive
Via Benzinga
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For February 24, 2025
Via Benzinga

Frequently Asked Questions

Is Veracyte, Inc. - Common Stock publicly traded?
Yes, Veracyte, Inc. - Common Stock is publicly traded.
What exchange does Veracyte, Inc. - Common Stock trade on?
Veracyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Veracyte, Inc. - Common Stock?
The ticker symbol for Veracyte, Inc. - Common Stock is VCYT on the Nasdaq Stock Market
What is the current price of Veracyte, Inc. - Common Stock?
The current price of Veracyte, Inc. - Common Stock is 27.22
When was Veracyte, Inc. - Common Stock last traded?
The last trade of Veracyte, Inc. - Common Stock was at 06/04/25 03:53 PM ET
What is the market capitalization of Veracyte, Inc. - Common Stock?
The market capitalization of Veracyte, Inc. - Common Stock is 1.84B
How many shares of Veracyte, Inc. - Common Stock are outstanding?
Veracyte, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS